Information Provided By: 
Fly News Breaks for January 18, 2018
ONTX
Jan 18, 2018 | 08:18 EDT
As reported earlier, Maxim analyst Jason McCarthy downgraded Onconova to Hold from Buy. McCarthy says that Independent Data Monitoring Committee's recommendation that NSPIRE phase 3 study of Rigosertib in myelodysplastic syndromes enrollment be expanded by over 50% to 135 more patients will take up more time and cost for a company with less than $5M in cash and a $7M per quarter burn rate, requiring Onconova to raise additional capital.
News For ONTX From the Last 2 Days
There are no results for your query ONTX
